Regional Access to Acute Ischemic Stroke Intervention

Background and Purpose— Benefit-risk ratios from recombinant tissue plasminogen activator (rtPA) therapy for acute ischemic stroke demonstrate lack of efficacy if intravenous administration is commenced beyond 3 hours of symptom onset. We undertook to enhance therapeutic effectiveness by ensuring equitable access to rtPA for patients affected by acute ischemic stroke within a 20 000 km2 population referral base served by a tertiary facility. Methods— Representatives of all provider groups involved in emergency medical services developed a Regional Acute Stroke Protocol (RASP), a coordinated regional system response by dispatch personnel, paramedics, physicians, community service providers, emergency and inpatient staff in community hospitals, and the tertiary facility acute stroke team. Results— As of July 26, 1999, all ambulance services in Southeastern Ontario began bypassing the closest hospital to deliver patients meeting the criteria for the RASP to the Kingston General Hospital. At 12 months, approximately 403 ischemic strokes have occurred in the region, the RASP has been activated 191 times, and 42 patients have received rtPA. Conclusions— We conclude that (1) acute stroke patients in Southeastern Ontario have improved access to interventions for stroke care; (2) geography of the region is not a barrier to access to interventions for patients with acute stroke; and (3) acute ischemic stroke patients treated with rtPA account for 5% of all acute strokes and 10% of all ischemic strokes in this region.

[1]  P. Langhorne,et al.  Organized Inpatient (Stroke Unit) Care for Stroke , 2008, The Cochrane database of systematic reviews.

[2]  A. Buchan,et al.  The Canadian Activase for Stroke Effectiveness Study (CASES): Interim results , 2000 .

[3]  A. Demchuk,et al.  Effectiveness of t-PA in acute ischemic stroke , 2000, Neurology.

[4]  D. Tanné,et al.  Initial clinical experience with IV tissue plasminogen activator for acute ischemic stroke: A multicenter survey , 1999, Neurology.

[5]  V. Hachinski,et al.  Canadian Guidelines for Intravenous Thrombolytic Treatment in Acute Stroke: A Consensus Statement of The Canadian Stroke Consortium , 1998, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[6]  M. Kaste,et al.  The ECASS 3-Hour Cohort , 1998, Cerebrovascular Diseases.

[7]  M. Kaste,et al.  The ECASS 3-hour cohort. Secondary analysis of ECASS data by time stratification. ECASS Study Group. European Cooperative Acute Stroke Study. , 1998, Cerebrovascular diseases.

[8]  J. Grotta,et al.  Intravenous tissue plasminogen activator for acute ischemic stroke: feasibility, safety, and efficacy in the first year of clinical practice. , 1998, Stroke.

[9]  Koroshetz Wj,et al.  Tissue plasminogen activator for acute ischemic stroke. , 1996, The New England journal of medicine.

[10]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .